pomalidomide
pomalidomide: developed by 1 company · 46 clinical trials tracked · 1 FDA decision.
pomalidomide evidence translation
What we can confirm
1 FDA record · 46 tracked trials
What it means
What to watch
Prepared research question
How could pomalidomide → RDY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 13 study sponsors
Related indications
Development Pipeline (1)
| Company | Phase |
|---|---|
| DR REDDYS LABORATORIES LTD (RDY) | Approved |
Clinical Trials (46)showing 10 most recent
A Phase 3, Multicenter, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etentamig in Combination With Pomalidomide Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (2L+ RRMM)
Primary endpoint: Safety Run-In: Number of Participants With Adverse Events (AE)s
TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)
Primary endpoint: Frequency and severity of treatment emergent adverse events (TEAEs)
A Randomized Phase II Trial for High-Risk Multiple Myeloma That is Refractory or in First Relapse With Daratumumab, Teclistamab (DT) Versus Daratumumab, Pomalidomide, Dexamethasone (DPd) or Daratumumab, Carfilzomib, Dexamethasone (DKd)
Primary endpoint: Minimal residual disease (MRD) negativity
A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CART) Therapy Directed Against BCMA and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma.
Primary endpoint: To demonstrate the superiority of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of PFS in participants with RRMM.
An Open-Label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab Plus Carfilzomib Versus Standard of Care Combination Regimens in Patients With Relapsed/Refractory Multiple Myeloma
Primary endpoint: Occurrence of Treatment Emergent Adverse Events (TEAEs)
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma
Primary endpoint: Dose-Limiting Toxicities (DLT)s of ABBV-453
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma
Primary endpoint: Progression Free Survival (PFS)
A Phase 1b Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Primary endpoint: Part 1: Number of Participants with Dose-limiting Toxicity (DLT)
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
Primary endpoint: Progression-Free Survival (PFS)
A Phase II Study of ISABELA: Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Primary endpoint: Overall Response Rate (ORR)
FDA Decisions1 records
Frequently asked questions
Who is developing pomalidomide?
pomalidomide is being developed by DR REDDYS LABORATORIES LTD.
How many clinical trials involve pomalidomide?
BioSniper tracks 46 clinical trials involving pomalidomide.
What is pomalidomide's latest FDA decision?
The most recent tracked FDA decision for pomalidomide is Tentative Approval for 1 INDICATIONS AND USAGE Pomalidomide capsules are a thalidomide analogue indicated for the treatment of adult patients: in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy ( 1.1 ). with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or, dated January 2, 2024.